A double-blind, randomized comparative study to investigate the morphine to hydromorphone conversion ratio in Japanese cancer patients by Inoue, Satoshi et al.
Title
A double-blind, randomized comparative study to investigate
the morphine to hydromorphone conversion ratio in Japanese
cancer patients
Author(s)Inoue, Satoshi; Saito, Yoji; Tsuneto, Satoru; Aruga, Etsuko;Ogata, Takeshi; Uemori, Mitsutoshi




© The Author(s) 2018. Published by Oxford University Press.
This is an Open Access article distributed under the terms of
the Creative Commons Attribution Non-Commercial License
(http://creativecommons.org/licenses/by-nc/4.0/), which
permits non-commercial re-use, distribution, and reproduction
in any medium, provided the original work is properly cited.





JJCO Japanese Journal ofClinical Oncology Japanese Journal of Clinical Oncology, 2018, 48(5) 442–449doi: 10.1093/jjco/hyy046
Advance Access Publication Date: 9 April 2018
Original Article
Original Article
A double-blind, randomized comparative study
to investigate the morphine to hydromorphone
conversion ratio in Japanese cancer patients
Satoshi Inoue1,*, Yoji Saito3, Satoru Tsuneto4, Etsuko Aruga5,
Takeshi Ogata1, and Mitsutoshi Uemori2
1Clinical Development Department, R&D Division, Daiichi Sankyo Co., Ltd, 2Biostatistics & Data Management
Department, R&D, Daiichi Sankyo Co., Ltd, Tokyo, 3Department of Anesthesiology, Shimane University Faculty of
Medicine, Shimane, 4Human Health Sciences, Graduate School of Medicine, Kyoto University, Kyoto, and
5Department of Palliative Medicine, Teikyo University School of Medicine, Tokyo, Japan
*For reprints and all correspondence: Satoshi Inoue, Clinical Development Department, R&D Division, Daiichi Sankyo
Co., Ltd, 1-2-58 Hiromachi, Shinagawa-ku, Tokyo 140-8710, Japan. E-mail: inoue.satoshi.g8@daiichisankyo.co.jp
Received 25 December 2017; Editorial Decision 20 March 2018; Accepted 22 March 2018
Abstract
Objective: To confirm the morphine to hydromorphone conversion ratio for hydromorphone (DS-
7113b) immediate-release tablets in cancer patients who achieved pain control with oral
morphine.
Methods: This was a multicenter, active-controlled, randomized, double-blind, parallel-group,
comparative study (July 2013 to December 2014) at 39 Japanese sites. Seventy-one patients (aged
>20 years) who had achieved pain control with morphine 60mg/day and 90mg/day were ran-
domly allocated 1:1 to hydromorphone immediate-release tablets at a dose converted at a hydro-
morphone:morphine ratio of 1:5 or 1:8, respectively, and treated for up to 5 days. The efficacy was
evaluated as the pain control ratio.
Results: The pain control ratio in the full analysis set was 83.3% (25/30) in the conversion ratio 1:5
group and 95.0% (38/40) in the conversion ratio 1:8 group, and both groups demonstrated highly suc-
cessful pain control. The incidence of adverse events was 46.7% (14/30) in the conversion ratio 1:5
group and 58.5% (24/41) in the 1:8 group; the difference was not clinically relevant. Frequently
observed adverse events (incidence ≥5%) were nausea, vomiting, diarrhea, somnolence and dyspnea.
Conclusions: A high pain control ratio was maintained by a switch at either conversion ratio, and
no notable difference was observed in the incidence of adverse events. A switch from morphine
to hydromorphone is effective at a dose converted at ratios of 1:5 and 1:8.
Key words: hydromorphone, morphine, cancer pain, opioid switching, conversion ratio, efficacy ratio
Introduction
The ‘three-step ladder for cancer pain relief’ from the World Health
Organization Guidelines recommends the use of Step 3 opioid
analgesics for moderate to severe pain (1), as they are the most
effective for relieving cancer pain and can provide successful pain
control (2). Morphine, oxycodone, and fentanyl are currently used
in Japan as Step 3 opioid analgesics (3).
The selective μ-opioid receptor agonist analgesic hydromorphone is
currently used clinically in 45 countries and regions in the world (4);
however, despite being a standard alternative for morphine (5–8), hydro-
morphone has not been developed for use in Japan. The metabolites of
hydromorphone are inactive (9), so it could potentially be used for
patients with renal impairment who cannot tolerate morphine, and its
approval in Japan would increase the treatment options for pain relief.
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There is no fixed opioid dose for cancer pain relief. The appro-
priate dose for each patient is considered to be that which produces
a successful analgesic effect with tolerable adverse drug reactions.
The converted dose is customarily calculated at the time of opioid
switching for each opioid based on its conversion ratio from mor-
phine, the standard drug. This is because of a lack of guidelines for
established doses for other opioids. As shown in Tables 1 and 2, sev-
eral conversion ratios of morphine to hydromorphone have been
reported and range between 2.7- and 8-fold (10), so a definite ratio
has not been established. A ratio of ~1:5 has been reported in many
papers (6,11–16), while a conversion ratio of 1:8 (or 1:7.5) report-
edly decreases the exposure (1,7,17,18). We therefore conducted a
study in Japanese cancer patients to confirm the morphine to hydro-
morphone conversion ratio for hydromorphone immediate-release
tablets and to confirm pain control by opioid switching using these
two typical conversion ratios.
Patients and methods
This study was conducted from July 2013 to December 2014 as a
multicenter, active-controlled, randomized, double-blind, parallel-
group comparison study, enrolling 71 patients at 39 sites in Japan
(participating sites are listed in Supplemental File 1). The study was
approved by the Institutional Review Board of each study site and
was conducted in accordance with the ethical principles of the
Declaration of Helsinki and Good Clinical Practice. Written
informed consent was obtained from all subjects prior to study
participation.
Participants
The study participants were cancer patients over 20 years of age
receiving opioid analgesics for pain relief in whom pain control was
achieved with regular administration of oral morphine either at
60mg/day or 90mg/day for at least 3 days before enrollment. Pain
control was defined as patients reporting a pain intensity score of 0
(none) or 1 (mild) and administered rescue medication no more than
twice daily. Exclusion criteria included patients for whom morphine
is contraindicated or relatively contraindicated, patients receiving
treatment with a monoamine oxidase inhibitor within 14 days of
registration, patients participating in another clinical trial within 28
days of registration, and patients with serious hepatic, renal or
respiratory disorders of Common Terminology Criteria for Adverse
Events Grade 3.
Study design
Patients that had achieved pain control by administration of morphine
were randomly allocated 1:1 to hydromorphone immediate-release
tablets (DS-7113b; Daiichi Sankyo, Tokyo, Japan) at a conversion
ratio of either 1:5 or 1:8. The study drug was provided by Daiichi
Sankyo Co., Ltd. The computer-generated random allocation sequence
was provided by Bell Medical Solutions Inc. (Tokyo, Japan), and was
stratified according to the daily morphine dose prior to beginning the
study (60 or 90mg/day). A double-dummy method was employed for
blinding, and subjects in the conversion ratio 1:5 group received
12mg/day of hydromorphone when their oral morphine dose was
60mg/day during the pre-treatment observation period, and hydro-
morphone 18mg/day when their oral morphine dose was 90mg/day.
Similarly, the subjects in the conversion ratio 1:8 group received
hydromorphone 7.5mg/day (oral morphine dose at 60mg/day during
the pre-treatment observation period) or 12mg/day (oral morphine
dose at 90mg/day during the pre-treatment observation period). The
dose of study drug was to remain unchanged and the study was dis-
continued as ‘pain control not maintained’ if a dose increase or
decrease was required. The study drug was administered if pain con-
trol was maintained, or for 5 days, whichever was shorter. The study
drug was orally administered six times daily in both groups with two
tablets of the active drug with or without additional placebo tablets to
maintain blinding, as one dose, but administration of two doses before
retiring was allowed in cases where midnight administration would be
difficult. Treatment was switched to appropriate analgesics after
achieving pain control or completion of study drug administration,
and the post-study observation was conducted.
Every day from baseline to treatment completion (or discontinu-
ation), patients evaluated their mean pain severity over the previous
24 h using a 4-step pain intensity scale [‘0, none’, ‘1, mild’, ‘2, mod-
erate’, ‘3, severe’], and visual analog scale (VAS) and recorded their
score in a diary once daily at a predetermined time. Sleep was evalu-
ated on a 4-point scale: 0 = very unsatisfactory or did not sleep at
Table 1. Conversion ratios in various textbooks/guidelines
Text/guideline Morphine Hydromorphone Conversion ratio Year of
publication
Principles of Analgesic use in the Treatment of Acute Pain and Cancer Pain (26) 30mg 7.5 mg 1:4a 2008
Bonica’s Management of Pain (27) 30mg 7.5 mg 1:4a 2010
60mg 6–8mg 1:3.75–5a
Oxford Textbook of Palliative Medicine 4th edition (10) – – 1:7.5 2010
20–60mgc 7.5 mg 1:2.7–8a
Opioid Therapy in the 21st Century (28) 30mg 7.5 mg 1:4a 2013
Palliative Care Formulary 5th edition (11) 1 mg 4–5mg (5–7.5 mg)b 1:5 2014
WHO Cancer Pain Relief 2nd edition (1) – – ≈8-fold 1996
ESMO: Management of cancer pain (7) 1 mg 7.5 mg 1:7.5 2011d
EAPC: Use of Opioid Analgesics in the Treatment of Cancer Pain (6) 1 mg 5mg 1:5 2012
NCCN: Adult Cancer Pain (8) 30mg 7.5 mg 1:4 2016
aConversion ratio converted by the actual dose.
bThe values in the parentheses are the conversion ratios reported by the pharmaceutical company, with the content excerpted directly from the footnotes of the
guidelines.
cExtensive survey data suggest that the relative potency of intramuscular:oral or subcutaneous:oral morphine of 1:6 changes to 1:2–3 with chronic dosing.
dThe latest edition, issued in 2012, includes no information on conversion ratio.
Jpn J Clin Oncol, 2018, Vol. 48, No. 5 443
Downloaded from https://academic.oup.com/jjco/article-abstract/48/5/442/4964830
by Kyoto Daigaku Nogaku-bu Toshoshitsu user
on 17 August 2018
all; 1 = markedly unsatisfactory; 2 = slightly unsatisfactory; 3 =
satisfactory.
Oral morphine hydrochloride solution was used as rescue medica-
tion when additional analgesia was required because of breakthrough
pain. However, the following were prohibited throughout the study: co-
administration of a monoamine oxidase inhibitor, opioid analgesics
other than rescue medication, and narcotic antagonists. Similarly, new
administration of systemic non-opioid analgesics, supplementary analge-
sics, bisphosphonates, anti-RANKL antibody preparations and changes
in dosage and administration were prohibited. New initiation of radio-
therapy, nerve block, percutaneous vertebroplasty, surgery, or cancer
chemotherapy or immunotherapy was also prohibited.
Outcomes
The primary efficacy endpoint was the pain control ratio. The cri-
teria for pain control were satisfaction for 2 days in all of the fol-
lowing items: study treatment continued at the same dose; pain
intensity either ‘0, none’ or ‘1, mild’; and administration of rescue
medication twice daily or less.
Secondary efficacy endpoints were changes in VAS and sleep
evaluation on each evaluation day, number of days required to
achieve pain control, and use of rescue medication. Sleep evaluation
was performed immediately prior to study drug administration, each
day during the study, 2 days after the study, and if/when patients
discontinued. Safety endpoints were adverse events, laboratory data,
vital signs and 12-lead electrocardiogram (ECG).
Statistical analysis
The sample size was calculated based on the assumptions that the
pain control ratio would be 90% for the 1:5 group and 80% for the
1:8 group. The target sample size was determined with reference to
previous clinical studies of oxycodone in Japan. Based on these
results, the pain control ratio was estimated to be 85–90% in patients
that were switched with an appropriate conversion ratio. If the pain
control ratio in the conversion ratio 1:5 group was also between 85%
and 90%, it was estimated that the pain control ratio would be
10–20% lower in the conversion ratio 1:8 group. This was examined
using 100,000 Monte Carlo simulations; therefore, 35 subjects in
each group were required to achieve a probability of >80% for
obtaining a difference of ≥10% when the difference in the true pain
control ratio was 20%, and for obtaining a difference of ≥0% when
the difference in the true pain control ratio was 10%. On this basis,
35 patients in each group were required to achieve a >80% pain con-
trol ratio that would be used to detect the difference of the point esti-
mates between groups (conversion ratio 1:5 group > conversion ratio
1:8 group).
In the efficacy analysis, the full analysis set (FAS) based on the
intention-to-treat principle was defined as the primary analysis set.
The primary analysis was to calculate the pain control ratio and its
95% confidence interval (CI) for each group. Fisher’s exact test was
used to compare the pain control ratio between groups, and the dif-
ference in the pain control ratio (conversion ratio 1:5 group − con-
version ratio 1:8 group) and its 95% CI (two-sided, normal
approximation) were calculated. The number of days required to
achieve pain control in each group was calculated.
As secondary analyses, summary statistics were calculated for
the change in VAS scores at treatment completion/discontinuation
from baseline. Analysis of covariance (ANCOVA) was also con-
ducted using the baseline VAS scores as a covariate, and difference
in the least square means (conversion ratio 1:5 group − conversion
ratio 1:8 group) and its 95% confidence interval (two-sided), and
corresponding P value were calculated. As sleep data analyses, the
Wilcoxon rank-sum test was used to compare groups at completion
of treatment/discontinuation. SAS System Release 9.2 (SAS Inc.,
Cary, NC, USA) was used for statistical analysis.
Results
Patients and treatment exposure
Figure 1 shows patient disposition. Enrolled patients were randomly
allocated—30 to the conversion ratio 1:5 group and 41 to the con-
version ratio 1:8 group—and all received the study drug. Of these,
Table 2. Conversion ratios reported by clinical studies and observational studies
Author(s) Study design Number of subjects Conversion ratio Journal Year of publication
Bruera E (12) Retrospective 733 1:5.33a Cancer 1996
Lawlor P (13) Retrospective 207 1:5.76a Pain 1997
Moriarty M (17) Blinded, crossover 100 1:7.5 J Clin Res 1999
Palangio M (14) Multicenter, joint, open-label 445 1:5 J Pain Symptom Manage 2002
Weinstein SM (18) Multicenter, joint, open-label 343 1:8 Clin Ther 2006
Wirz S (16) Prospective observational 50 1:5 Clin J Pain 2006
Wallace M (15) Multicenter, joint, open-label 148 1:5 J Int Med Res 2008
aConversion ratio converted by the actual dose.
Figure 1. Patient disposition.
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27 in the conversion ratio 1:5 group and 38 in the conversion ratio
1:8 group completed the study. Although random allocation was
performed following correct procedures, this imbalance in the num-
ber of patients between groups occurred by chance. Three subjects
in each group discontinued the study, and the main reasons for
study discontinuation were adverse events and withdrawal of
consent.
A total of 70 subjects were included in the FAS after excluding
one subject in the conversion ratio 1:8 group for whom evaluable
efficacy data were not available. Table 3 shows the demographics of
the FAS. Approximately 85% of the conversion ratio 1:5 group was
male compared with 60% of the conversion ratio 1:8 group.
Subjects with a pain intensity score of 1 accounted for ~55% of the
1:5 and 70% of the 1:8 groups. No significant intergroup difference
was observed for other items. Almost 80% of the subjects received
the oral morphine dose of 60mg/day and ~20% received the dose of
90mg/day.
Efficacy
The pain control ratio in the FAS was 83.3% (25/30) in the conver-
sion ratio 1:5 group and 95.0% (38/40) in the conversion ratio 1:8
group, with a high pain control ratio maintained in both groups
(Table 4). The intergroup difference in the pain control ratio (95%
CI) was −11.7% (−26.6 to 3.3), which was not statistically signifi-
cant (Fisher’s exact test: P = 0.1298). Pain control was not main-
tained in seven subjects (conversion ratio 1:5 group: 5, conversion
ratio 1:8 group: 2). This was owing to non-response in three sub-
jects (conversion ratio 1:5 group: 2; conversion ratio 1:8 group: 1),
discontinuation due to onset of adverse drug reactions in two sub-
jects (one patient in each group), withdrawal of consent by one sub-
ject (1:5 group), and non-achievement due to deviation from pain
evaluation window in one subject (1:5 group).
Table 5 shows the number of days required for achieving pain
control in each group in the FAS. Pain control was maintained on
Day 2 in >80% of the subjects in both groups.
Table 6 shows the results of the ANCOVA of the magnitude of
change in VAS score at treatment completion/discontinuation in the
FAS. Figure 2 shows a transition diagram of VAS score in the FAS.
The mean (±standard deviation) magnitude of change in VAS
score at treatment completion/discontinuation in the FAS was 0.4 ±
10.47mm in the conversion ratio 1:5 group and 0.2 ± 7.73mm in
the conversion ratio 1:8 group, showing little change in VAS score
from baseline in either group. The difference in least square mean
Table 3. Baseline demographic and clinical characteristics
Conversion ratio 1:5 group N = 30 Conversion ratio 1:8 group N = 40
Age (years) Mean ± SD 65.2 ± 11.22 66.1 ± 9.10
Sex, n (%) M 26 (86.7) 25 (62.5)
F 4 (13.3) 15 (37.5)
Body weight (kg) Mean ± SD 53.23 ± 10.319 51.61 ± 9.065
BMI (kg/m2) Mean ± SD 19.93 ± 3.339a 20.01 ± 2.859
Underlying tumor type, n (%) Head and neck 0 (0.0) 1 (2.5)
Lung 15 (50.0) 21 (52.5)
Breast 3 (10.0) 5 (12.5)
Gastrointestinal 10 (33.3) 4 (10.0)
Liver/gallbladder/pancreatic 0 (0.0) 1 (2.5)
Urinary/reproductive organs 1 (3.3) 5 (12.5)
Other 1 (3.3) 3 (7.5)
ECOG PS, n (%) 0 6 (20.0) 13 (32.5)
1 13 (43.3) 20 (50.0)
2 6 (20.0) 6 (15.0)
3 5 (16.7) 1 (2.5)
4 0 (0.0) 0 (0.0)
VAS score (mm) Mean ± SD 15.3 ± 12.61 14.0 ± 10.48
Pain intensity, n (%) 0. None (not painful) 13 (43.3) 12 (30.0)
1. Mild (somewhat painful) 17 (56.7) 28 (70.0)
2. Moderate (painful) 0 (0.0) 0 (0.0)
3. Severe (very painful) 0 (0.0) 0 (0.0)
Pre-study oral morphine dose, n (%) 60mg/day 24 (80.0) 33 (82.5)
90 mg/day 6 (20.0) 7 (17.5)
BMI, body mass index; ECOG PS, Eastern Cooperative Oncology Group Performance Status; SD, standard deviation; VAS, visual analog scale.
Table 4. Successful pain control ratio (FAS)
N Successful pain control
n (%, achievement ratio)
95% CI Intergroup differencea 95% CI for intergroup difference P valueb
Conversion ratio 1:5 group 30 25 (83.3) (65.3–94.4) −11.7 (−26.6–3.3) 0.1298
Conversion ratio 1:8 group 40 38 (95.0) (83.1–99.4)
aConversion ratio 1:5 group − conversion ratio 1:8 group.
bFisher’s exact method.
CI, confidence interval; FAS, full analysis set.
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(95% CI) was 0.5 mm (−3.8 to 4.8), which was not statistically sig-
nificant and indicated no intergroup difference (ANCOVA: P =
0.8287). VAS score did not increase after switching from morphine
to hydromorphone in either group, and pain remained favorably
controlled at completion/discontinuation of hydromorphone
therapy.
Tabulation of daily use of rescue medication in the FAS showed
that the frequency of use was 0 or once in more than 80% of the
subjects in both groups on each observation day up to Day 3. The
mean frequency of daily use of rescue medication after the start of
administration on Day 1 up to Day 3 was less than once in both
groups, and the frequency of use of rescue medication was not
greatly increased compared with baseline use of oral morphine
hydrochloride solution.
Table 7 shows the cross-frequency table of sleep assessment in
the FAS at treatment completion/discontinuation. More than 70%
of the subjects in both groups were assessed as either ‘2, slightly
unsatisfactory’ or ‘3, satisfactory’, and no subject was assessed as
aggravated compared with baseline. A comparison of sleep quality
assessments between groups revealed no significant difference in the
score at treatment completion/discontinuation (Wilcoxon’s rank-
sum test: P = 0.7303).
Safety and tolerability
All 71 randomized subjects who received the study drug (30 in the
conversion ratio 1:5 group and 41 in the conversion ratio 1:8 group)
were included in the safety analysis. The incidence of adverse events
was 46.7% (14/30) in the conversion ratio 1:5 group and 58.5%
(24/41) in the conversion ratio 1:8 group, showing no significant
intergroup difference. Frequently observed adverse events (incidence
of ≥5%, Table 8) were nausea, vomiting, diarrhea, somnolence and
dyspnea.
The incidence of serious adverse events was 10.0% (3/30) in the
conversion ratio 1:5 group and 9.8% (4/41) in the conversion ratio
1:8 group, showing no significant intergroup difference. Of these,
events judged to be causally related to the study drug were observed
in one subject (stupor) in the conversion ratio 1:5 group and three
subjects (enterocolitis, ileus and nausea in one subject each) in the
conversion ratio 1:8 group. All patients had recovered by the study
completion.
There were no notable changes in laboratory data or vital signs,
and evaluation of 12-lead ECG did not show clinically problematic
QT prolongation.
Discussion
This study investigated the efficacy and safety of switching from
morphine to hydromorphone immediate-release tablets at the con-
version ratio of 1:5 or 1:8 in cancer patients with adequate pain
control with oral morphine at 60 or 90mg/day. The pain control
ratio in the FAS, the primary efficacy endpoint, was 83.3% (25/30)
in the conversion ratio 1:5 group and 95.0% (38/40) in the conver-
sion ratio 1:8 group. The point estimate of the pain control ratio
was higher in the 1:8 group than that in the 1:5 group. While no
statistically significant difference was observed, these results did not
support our initial hypothesis (of a higher pain control ratio in the
1:5 group than in the 1:8 group), but demonstrated high pain con-
trol ratios in both groups. No intergroup difference was observed in
the incidence of adverse events, and the results did not greatly differ
from those of previous reports (19,20).
The subjects in this study were randomized at a 1:1 ratio but 41
and 30 patients were allocated to the conversion ratio 1:8 and 1:5
groups, respectively. The imbalance in the allocated number of sub-
jects would not affect evaluation of efficacy and safety because the
random allocation was conducted according to the correct proce-
dures. The imbalance in the number of subjects occurred by chance.
Although indexes of efficacy are not the same because they are
also used for patients with non-cancer pain, the pain control ratio
ranged between 50% and 84% in reports that evaluated pain con-
trol at the time of opioid switching (21–24). The pain control ratios
(83.3% and 95.0% in the conversion ratio 1:5 and 1:8 groups,
respectively) in this study were comparable to those in the above
reports, and efficacy was confirmed to be clinically unproblematic.
Both groups showed high pain control after switching to hydromor-
phone in VAS scores as the secondary endpoint and no intergroup
difference was observed.
Prior to clinical use in Japan, the conversion ratios versus mor-
phine ranged widely from 2.7- to 8-fold, so a more appropriate con-
version ratio had to be confirmed. Based on the dose conversion
ratios of 1:5 for the currently marketed hydromorphone products
Exalgo (19) and Jurnista (20), 1:7.5 for Palladone (25), and ~1:8
recommended in the WHO guidelines (1), we investigated two
groups with conversion ratios of 1:5 and 1:8 in this study. Some
reports investigated the conversion ratio at switching, whereas
others investigated the conversion ratio based on the final dose and
the subsequent dose adjustment period. We evaluated pain control
at the time of switching for the purpose of confirming information
Table 5. Number of days required for achievement of pain control
(FAS)
n (%) Conversion ratio 1:5
group (N = 30)
Conversion ratio 1:8
group (N = 40)
Number of achievers 25 (83.3) 38 (95.0)
Day 2 24 (80.0) 37 (92.5)
Day 3 0 1 (2.5)
Day 4 1 (3.3) 0
Day 5 0 0
Number of non-achievers 5 (16.7) 2 (5.0)
FAS, full analysis set.
Table 6. ANCOVA of the change in VAS score (treatment
completion/discontinuation) (FAS)
Conversion ratio
1:5 group (N = 30)
Conversion ratio
1:8 group (N = 40)




Least square mean 0.6 0.1
Difference in least square
meana
0.5
95% confidence interval (−3.8–4.8)
P value 0.8287
aConversion ratio 1:5 group − conversion ratio 1:8 group.
ANCOVA, analysis of covariance; FAS, full analysis set.
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for safely conducting opioid switching. The results in both groups in
our study showed that opioid switching was not clinically problem-
atic, so the conversion ratio of hydromorphone from morphine was
determined in the range of 1:5 and 1:8, and effective and safe
switching was considered possible by calculating the converted dose.
These findings indicate that the conversion ratio from morphine falls
in the range of 1:5–1:8, suggesting that the conversion ratio to
hydromorphone is not fixed to a specific value but can vary within a
certain range. This range is consistent with any conversion ratios
(1:5 for Exalgo, Jurnista, etc. and 1:7.5 for Palladone) calculated
based on the converted doses listed in the package inserts of cur-
rently marketed hydromorphone formulations. However, the opti-
mal dose after switching should be determined at the time of actual
Figure 2. Changes in visual analog scale scores in the full analysis set (FAS).
Table 7. Analysis of sleep quality assessment (cross-frequency table)
Baseline Treatment completion/discontinuation Total n
(%)
P valuea P valueb
0. Very
unsatisfactory or









0. Very unsatisfactory or did
not sleep at all
0 1 0 0 1 (3.3) 0.3667 0.7303
1. Markedly unsatisfactory 0 3 3 2 8 (26.7)
2. Slightly unsatisfactory 0 4 8 1 13 (43.3)
3. Satisfactory 0 0 1 7 8 (26.7)




0. Very unsatisfactory or did
not sleep at all
0 0 0 0 0 (0.0) 0.2657
1. Markedly unsatisfactory 0 0 1 0 1 (2.5)
2. Slightly unsatisfactory 1 4 17 5 27 (67.5)
3. Satisfactory 0 0 6 6 12 (30.0)
Total n (%) 1 (2.5) 4 (10.0) 24 (60.0) 11 (27.5) 40
aWilcoxon’s signed rank test.
bWilcoxon’s rank-sum test.




1:5 group N = 30
Conversion ratio
1:8 group N = 41
Number of subjects who
developed adverse events (%)
14 (46.7) 24 (58.5)
Nausea 2 (6.7) 6 (14.6)
Vomiting 2 (6.7) 3 (7.3)
Somnolence 3 (10.0) 2 (4.9)
Diarrhea 0 (0.0) 4 (9.8)
Dyspnea 2 (6.7) 0 (0.0)
SOC, system organ class; PT, preferred term.
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opioid switching and should include considerations of the reasons
for switching and patients’ conditions, rather than by a mere numer-
ical conversion using the conversion ratio.
This study has some limitations. First, our data do not apply to
patients requiring opioid switching in a clinical situation, because
the subjects in our study had achieved pain control with morphine
and had no safety problems. Second, the study was designed to
switch the total morphine dose to hydromorphone only in patients
receiving daily morphine doses of 60 or 90mg, and switching at
high doses exceeding morphine 90mg/day and stepwise switching
were not investigated. Finally, the study was completed by confirm-
ing successful pain control after switching, and the relationship with
the optimal dose after switching, including subsequent titration, was
not investigated.
Conclusions
Successful pain control was maintained when switching from mor-
phine to hydromorphone with a conversion ratio of 1:5 or 1:8 in
Japanese cancer patients who had achieved pain control with oral
morphine, with no significant difference between groups. No inter-
group difference was observed in the incidence of adverse events or
serious adverse events. A conversion ratio between 1:5 and 1:8 is
considered clinically appropriate for a switch from morphine to
hydromorphone for pain control in cancer patients.
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Supplementary data are available at Japanese Journal of Clinical
Oncology online.
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